All News
Filter News
Found 136 articles
-
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
3/1/2023
Chroma Medicine, Inc. announced the completion of a $135 million Series B financing led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.
-
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
1/5/2023
Alterome Therapeutics, Inc. today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Generate Biomedicines Uses AI to Create Proteins That Have Never Existed
12/1/2022
Generate Biomedicines today published a preprint describing a breakthrough in protein science that unlocks the ability to generate novel proteins.
-
SeQure Dx Emerges From Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies for Biopharma Partners, Physicians, and Patients
11/16/2022
SeQure Dx has announced its emergence from stealth mode with an aim to partner with biopharma companies developing gene editing therapeutics.
-
Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia
11/11/2022
Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio.
-
Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors
10/26/2022
Expansion Therapeutics, Inc. today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.
-
Chroma Medicine Welcomes Spark Therapeutics Co-Founder and Former Founding CEO Jeff Marrazzo to Board of Directors
10/4/2022
Chroma Medicine , Inc. today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors.
-
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
9/20/2022
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB).
-
Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D.
6/30/2022
Myeloid Therapeutics, Inc. today announced that it has expanded its Board of Directors with the appointments of industry leaders Stanley Frankel, M.D., FACP and Brett Kaplan, M.D.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor
5/24/2022
Chroma Medicine Strengthens Leadership with Addition of George Golumbeski to Board of Directors and John Maraganore as Strategic Advisor.
-
Etcembly Appoints Scott Cuthill as Chief Business Officer
3/15/2022
Etcembly today announced the appointment of Scott Cuthill PhD, as Chief Business Officer (CBO). The Oxford based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies.
-
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
-
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
-
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
-
Newpath is guided by the ethos: “Do the right thing and good things will happen."
-
Money on the Move: November 17 – 23
11/24/2021
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash. -
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
-
Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing
11/17/2021
Chroma Medicine, Inc., a new genomic medicine company pioneering epigenetic editing, launched with $125M in financing.